Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
NCT07092748

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors

Led by Zhejiang Hisun Pharmaceutical Co. Ltd. · Updated on 2025-07-30

110

Participants Needed

1

Research Sites

180 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a Phase Ia/Ib, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, and preliminary efficacy of HS387 in subjects with advanced solid tumors. It includes two parts: the dose escalation study (Phase Ia) and the dose expansion study (Phase Ib)

CONDITIONS

Official Title

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Men or women aged 18 to 75 years
  • Advanced solid tumors with failure, intolerance to standard treatment, or no standard therapy available
  • Expected survival of at least 3 months
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • At least one evaluable lesion (Phase Ia) or measurable lesion (Phase Ib) per RECIST 1.1
  • Adequate organ function at screening
  • Negative pregnancy test for females of childbearing potential before first dosing
  • Agreement to use effective contraception during the study and for 3 months after last dose for males and females of childbearing potential
Not Eligible

You will not qualify if you...

  • Received investigational drugs or unapproved treatments within 4 weeks before first dose
  • Active infection
  • Meningeal metastases or symptomatic central nervous system metastases
  • Significant problems absorbing oral drugs
  • Interstitial lung disease
  • Pregnant or lactating women
  • History of allogeneic organ or hematopoietic stem cell transplantation
  • Major surgery within 4 weeks before first dose
  • Previous treatment with KIF18A inhibitor
  • Other factors deemed unsuitable by the Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

Zhejiang Cancer hospital

Hangzhou, Zhejiang, China

Actively Recruiting

Loading map...

Research Team

W

WEI QU

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Phase Ia/ Ib Study of HS387 in Subjects With Advanced Solid Tumors | DecenTrialz